Fabry Disease Markets 2018-2028 by Gender and 5-Year Age Cohort

DUBLIN, July 16, 2018 /PRNewswire/ --

The "Epiomic Epidemiology Series: Fabry Disease Forecast In 21 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The Epiomic Epidemiology Series Forecast Report on Fabry Disease in 21 Major Markets

Fabry disease is a lysosomal storage disorder, caused by a genetic defect in the alpha-galactosidase-A gene (aGLA-gene), localized on the long arm of the X-chromosome (Xq22). This gene is essential in the breakdown of fatty substances, otherwise substances like globotriaosylceramide, will accumulate in the arteries, narrowing them and reducing blood flow around the body. It is a multi-system disorder characterised by dermatologic angiokeratoma corporis diffusum and purpura haemorrhagica nodularis, but also affects ocular, auditory, cardiac, digestive and renal systems.

This report provides the current prevalent population for Fabry Disease across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Austria, Portugal, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Fabry disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Fabry disease include:

    --  Angiokeratoma
    --  Cornea verticillata (corneal whorling)
    --  Hearing loss
    --  Tinnitus
    --  Proteinuria
    --  Cardiac hypertrophy & arrhythmias

    --  Sweating dysfunction

Reasons to buy

    --  Able to quantify patient populations in global Fabry disease market to
        target the development of future products, pricing strategies and launch
        plans.
    --  Gain further insight into the prevalence of the subdivided types of
        Fabry disease and identify patient segments with high potential.
    --  Delivery of more accurate information for clinical trials in study
        sizing and realistic patient recruitment for various countries.
    --  Provide a level of understanding on the impact from specific co-morbid
        conditions on Fabry disease prevalent population.
    --  Identify sub-populations within Fabry disease which require treatment.
    --  Gain an understanding of the specific markets that have the largest
        number of Fabry disease patients.

Key Topics Covered:

    1. Introduction
    2. Cause Of The Disease
    3. Risk Factors & Prevention
    4. Diagnosis Of The Disease
    5. Variation By Geography/Ethnicity
    6. Disease Prognosis & Clinical Course
    7. Key Comorbid Conditions / Features Associated With The Disease
    8. Methodology For Quantification Of Patient Numbers
    9. Top-Line Prevalence For Fabry Disease
    10. Features Of Fabry Disease Patients
    11. Abbreviations Used In The Report
    12. Other Services & Solutions
    13. Reports & Publications
    14. Online Epidemiology Databases
    15. Online Pharmaceutical Pricing Database
    16. References

    17. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/z2t4cx/fabry_disease?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/fabry-disease-markets-2018-2028-by-gender-and-5-year-age-cohort-300681361.html

SOURCE Research and Markets